Patents Assigned to Ablynx N.V.
-
Publication number: 20220251183Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: April 13, 2022Publication date: August 11, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Publication number: 20220242958Abstract: The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.Type: ApplicationFiled: December 2, 2021Publication date: August 4, 2022Applicant: Ablynx N.V.Inventors: Annelies Roobrouck, Catelijne Stortelers, Peter Vanlandschoot, Stephanie Staelens, Miguel Conde, Hugo Soares, Dominique Schols
-
Patent number: 11384151Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.Type: GrantFiled: July 9, 2019Date of Patent: July 12, 2022Assignee: Ablynx N.V.Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Neotere Ververken
-
Publication number: 20220213215Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: December 17, 2021Publication date: July 7, 2022Applicants: Ablynx N.V., SanofiInventors: Daniel Janssen, Carlo Boutton, Evelyne Dombrecht, Bram Laukens, Paolo Meoni, Lily Pao, Jan Pype, Peter Schotte, Benedikte Serruys, Ana Paula Vintem, Diane Van Hoorick
-
Patent number: 11370835Abstract: Processes and methods of purifying or separating Single Domain Antigen Binding (SDAB) molecules that include one or more single binding domains (e.g., one or more nanobody molecules), substantially devoid of a complementary antibody domain and an immunoglobulin constant region, using Protein A-based affinity chromatography, are disclosed.Type: GrantFiled: September 26, 2018Date of Patent: June 28, 2022Assignee: Ablynx N.V.Inventors: Paul R. Brown, Scott Andreas Tobler, Andrew M. Wood, Austin Wayne Boesch
-
Publication number: 20220177566Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220177564Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220177565Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
-
Publication number: 20220175923Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.Type: ApplicationFiled: November 22, 2021Publication date: June 9, 2022Applicant: Ablynx N.V.Inventors: Jason E. Fernandez, Daniel A. Dixon, Andrea Paulson
-
Publication number: 20220153854Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISV binds to OX40L and at least two ISVDs bind to IL-13. The present disclosure also provides nucleic acids, vectors and compositions.Type: ApplicationFiled: September 24, 2021Publication date: May 19, 2022Applicants: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Klaus Erb, Eric Lorent, John Park, Robert Resnick, Melanie Rieger, Bernd Weigle
-
Patent number: 11332525Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.Type: GrantFiled: October 15, 2021Date of Patent: May 17, 2022Assignees: Ablynx N.V., SanofiInventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
-
Patent number: 11332519Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.Type: GrantFiled: November 17, 2016Date of Patent: May 17, 2022Assignee: Ablynx N.V.Inventor: Marie-Ange Buyse
-
Publication number: 20220135657Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: March 29, 2021Publication date: May 5, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11319364Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: May 3, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11312764Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: November 26, 2019Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11312765Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: GrantFiled: March 29, 2021Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11312788Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: GrantFiled: July 17, 2018Date of Patent: April 26, 2022Assignee: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20220119497Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).Type: ApplicationFiled: August 23, 2021Publication date: April 21, 2022Applicant: Ablynx N.V.Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
-
Publication number: 20220119512Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).Type: ApplicationFiled: December 27, 2021Publication date: April 21, 2022Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton
-
Patent number: 11306139Abstract: The present invention relates to glycosylated immunoglobulin variable domains, and in particular to glycosylated immunoglobulin single variable domains (the latter also being referred to herein by means of the abbreviation “ISF” or “ISVD”). The present invention relates to glycosylated immunoglobulin heavy-chain variable domains (also referred to herein as “VH domains”), and in particular to glycosylated immunoglobulin heavy-chain ISVD's. The invention in particular relates to immunoglobulin (single) variable domains that are glycosylated in such a way that the binding of said immunoglobulin (single) variable domains by so-called “pre-existing antibodies” is prevented and/or reduced (i.e. partially or essentially completely) compared to the same immunoglobulin (single) variable domain without the glycosylation of the invention being present.Type: GrantFiled: March 18, 2016Date of Patent: April 19, 2022Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Carlo Boutton